Criteria Bio Ventures
To add a bio or update investment portfolio, please click update information.
Investment Portfolio
Cytospire Therapeutics
5 May 2026
Cytospire Therapeutics secures £61m Series A led by 4BIO Capital for cancer therapies that activate the body’s immune cells
Cytospire Therapeutics develops multispecific immune cell engager antibodies designed to enhance and direct the activity of the body’s immune system. Its platform targets gamma delta T cells to generate anti tumour immune responses for patients with cancer and other diseases.
NRG Therapeutics
8 Sept 2025
NRG Therapeutics lands £50m Series B led by SV Health Investors to advance neurodegenerative disease therapies
NRG Therapeutics develops oral small-molecule drugs targeting mitochondrial dysfunction, aiming to slow or halt neurodegenerative diseases such as ALS and Parkinson’s through disease-modifying treatments.
Criteria Bio Ventures
More venture news
- 12 Aug 2026
MindgardMindgard secures £22m Series A led by Album VC to test and defend AI systems against adversarial attack
Series ACybersecurity - 12 Aug 2026
CytixCytix raises a £5m Series A round led by Northern Gritstone to manage the security risk of AI-driven software change
Series ACybersecurity - 29 Jul 2026
LemonEdgeLemonEdge announced £16m Series A round led by Blackstone Innovations Investments for a fund accounting platform built for private markets
Series AFintech
